Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Advances in the management of inflammatory bowel disease

Date

Authors

Grimpen, Florian

Pavli, Paul

Publisher

Blackwell Science Asia

Abstract

Our understanding of inflammatory bowel diseases (IBD) is constantly evolving, and many new treatment options have emerged recently. This review critically examines the evidence for these new developments and aims to provide an overview for medical professionals involved in the care of patients with IBD. Proposed changes in the use of aminosalicylates, immunosuppressants and biological agents are described, and the evidence for several promising novel agents is reviewed.

Keywords

Keywords: abatacept; adalimumab; aminosalicylic acid; azathioprine; basiliximab; C reactive protein; certolizumab pegol; corticosteroid; daclizumab; immunosuppressive agent; infliximab; mercaptopurine; mesalazine; natalizumab; salazosulfapyridine; tioguanine; tumor Crohn's disease; IBD; Review management; Ulcerative colitis

URI

http://hdl.handle.net/1885/51667

Collections

ANU Research Publications

Source

Internal Medicine Journal

Type

Journal article

DOI

10.1111/j.1445-5994.2010.02163.x

Restricted until

2037-12-31

Downloads

File

Description

01_Grimpen_Advances_in_the_management_of_2010.pdf (119.77 KB)